niceatm
iccvam
conven
intern
workshop
review
state
scienc
human
veterinari
vaccin
potenc
safeti
test
method
identifi
opportun
advanc
new
improv
method
reduc
refin
replac
anim
use
six
topic
address
detail
speaker
workshop
particip
report
seri
six
report
workshop
report
second
seri
provid
recommend
current
futur
use
nonanim
method
strategi
veterinari
vaccin
potenc
test
workshop
particip
recommend
futur
effort
replac
anim
use
give
prioriti
vaccin
use
larg
number
anim
per
test
mani
serial
produc
annual
involv
signific
anim
pain
distress
procedur
function
protect
antigen
identifi
involv
foreign
animalzoonot
organ
danger
human
involv
pathogen
easili
spread
wildlif
popul
vaccin
identifi
highest
prioriti
rabi
leptospira
spp
clostridium
spp
erysipela
foreign
anim
diseas
fad
poultri
diseas
fish
diseas
research
identif
purif
character
vaccin
protect
antigen
veterinari
vaccin
also
identifi
prioriti
critic
knowledg
data
gap
includ
opportun
appli
new
scienc
technolog
recommend
includ
investig
rel
impact
variou
adjuv
antigen
quantif
assay
investig
extract
method
could
use
vaccin
contain
adjuv
interfer
antigen
assay
review
current
statu
rabi
tetanu
human
vaccin
vitro
potenc
method
potenti
applic
correspond
veterinari
vaccin
workshop
particip
recommend
enhanc
intern
harmon
cooper
closer
collabor
human
veterinari
research
expedit
progress
implement
workshop
recommend
expect
advanc
altern
vitro
method
veterinari
vaccin
potenc
test
benefit
anim
welfar
replac
anim
use
ensur
continu
protect
human
anim
health
veterinari
vaccin
contribut
improv
human
anim
health
welfar
prevent
control
infecti
agent
caus
diseas
death
howev
test
necessari
ensur
vaccin
effect
safeti
involv
larg
number
anim
signific
pain
distress
unit
state
interag
coordin
committe
valid
altern
method
iccvam
nation
toxicolog
program
interag
center
evalu
altern
toxicolog
method
niceatm
promot
scientif
valid
regulatori
accept
test
method
accur
assess
safeti
chemic
product
reduc
refin
less
pain
distress
replac
anim
use
accordingli
niceatm
iccvam
recent
identifi
vaccin
potenc
safeti
test
one
four
highest
prioriti
iccvam
interag
committe
feder
agenc
charg
law
evalu
new
revis
altern
test
method
regulatori
applic
iccvam
member
repres
us
feder
regulatori
research
agenc
requir
use
gener
dissemin
safeti
test
data
includ
depart
agricultur
usda
regul
veterinari
vaccin
food
drug
administr
fda
regul
human
vaccin
iccvam
perman
interag
committe
nation
institut
environment
health
scienc
nieh
niceatm
niceatm
administ
iccvam
provid
scientif
oper
support
iccvamrel
activ
conduct
intern
valid
studi
promis
new
safeti
test
method
niceatm
iccvam
serv
critic
public
health
role
translat
research
advanc
bench
standard
safeti
test
method
use
regulatori
practic
prevent
diseas
injuri
promot
advanc
develop
use
scientif
valid
altern
method
human
veterinari
vaccin
test
niceatm
iccvam
organ
intern
workshop
altern
method
reduc
refin
replac
use
anim
vaccin
potenc
safeti
test
state
scienc
futur
direct
workshop
held
nation
institut
health
bethesda
maryland
septemb
organ
conjunct
european
centr
valid
altern
method
ecvam
japanes
center
valid
altern
method
jacvam
health
canada
workshop
address
state
scienc
human
veterinari
vaccin
potenc
safeti
test
particip
develop
recommend
futur
progress
three
major
area
vitro
replac
method
potenc
test
reduct
refin
method
potenc
test
reduct
refin
replac
method
vaccin
safeti
test
report
prepar
three
topic
human
vaccin
three
topic
veterinari
vaccin
report
address
method
strategi
replac
anim
use
potenc
test
veterinari
vaccin
goal
intern
workshop
identifi
promot
implement
current
avail
accept
altern
method
reduc
refin
replac
use
anim
human
veterinari
vaccin
potenc
safeti
test
review
state
scienc
altern
method
identifi
knowledg
data
gap
need
address
identifi
priorit
research
develop
valid
effort
need
address
gap
order
advanc
altern
method
also
ensur
continu
protect
human
anim
health
workshop
organ
four
plenari
session
three
breakout
group
session
breakout
session
workshop
particip
identifi
criteria
priorit
vaccin
potenc
safeti
test
futur
altern
test
method
develop
identifi
high
prioriti
use
criteria
review
current
state
scienc
altern
method
discuss
way
promot
implement
avail
method
identifi
knowledg
data
gap
need
address
identifi
priorit
research
develop
valid
effort
need
address
gap
order
advanc
altern
method
ensur
continu
protect
human
anim
health
workshop
open
plenari
session
expert
scientist
regulatori
author
unit
state
europ
japan
canada
outlin
import
vaccin
human
anim
health
describ
nation
intern
regulatori
test
requir
human
veterinari
vaccin
author
emphas
follow
regulatori
approv
vaccin
test
requir
ensur
subsequ
product
lot
pure
safe
suffici
potent
gener
protect
immun
respons
peopl
anim
second
plenari
session
address
method
accept
method
develop
requir
use
anim
assess
potenc
vaccin
follow
breakout
session
discuss
state
scienc
recommend
futur
progress
vitro
potenc
test
human
veterinari
vaccin
paper
provid
workshop
recommend
advanc
use
develop
altern
method
replac
anim
potenc
test
veterinari
vaccin
recommend
human
vaccin
avail
elsewher
proceed
third
plenari
session
address
potenc
test
method
refin
procedur
avoid
lessen
pain
distress
incorpor
earlier
human
endpoint
use
antibodi
quantif
test
instead
challeng
test
method
approach
reduc
number
anim
requir
test
breakout
group
discuss
state
scienc
develop
recommend
futur
progress
workshop
recommend
advanc
use
develop
altern
method
reduc
refin
anim
use
potenc
test
human
vaccin
veterinari
vaccin
avail
respect
paper
proceed
final
plenari
session
address
method
approach
reduc
refin
replac
anim
use
assess
safeti
serial
product
lot
human
veterinari
vaccin
breakout
group
discuss
state
scienc
develop
recommend
advanc
altern
method
vaccin
safeti
test
workshop
recommend
advanc
use
develop
altern
method
safeti
test
human
vaccin
veterinari
vaccin
avail
proceed
strict
regul
guidelin
design
ensur
everi
veterinari
vaccin
distribut
unit
state
pure
safe
potent
effect
estim
serial
batch
veterinari
vaccin
releas
annual
unit
state
approxim
differ
product
protect
anim
differ
anim
diseas
given
mani
inactiv
vaccin
still
requir
anim
potenc
test
signific
number
anim
necessari
veterinari
vaccin
contribut
health
well
peopl
anim
addit
control
prevent
diseas
companion
domest
anim
vaccin
help
ensur
safe
effici
global
food
suppli
reduc
transmiss
zoonot
foodborn
infect
anim
peopl
vaccin
also
reduc
need
lowlevel
antibiot
control
diseas
food
anim
due
number
anim
use
annual
releas
veterinari
vaccin
global
regulatori
agenc
activ
encourag
evalu
develop
implement
novel
approach
reduc
refin
replac
use
anim
vaccin
safeti
potenc
product
releas
test
potenc
test
procedur
mani
veterinari
vaccin
still
requir
use
anim
therefor
develop
valid
addit
replac
test
could
significantli
benefit
anim
health
welfar
workshop
particip
priorit
veterinari
vaccin
target
develop
valid
vitro
replac
test
criteria
priorit
includ
vaccin
use
larg
number
anim
per
test
mani
serial
produc
annual
vaccin
involv
signific
anim
pain
distress
test
procedur
vaccin
function
protect
antigen
identifi
character
vaccin
involv
foreign
animalzoonot
organ
vaccin
involv
pathogen
easili
spread
wildlif
popul
base
criteria
follow
vaccin
given
highest
prioriti
develop
altern
replac
method
rabi
vaccin
leptospira
spp
vaccin
clostridium
spp
vaccin
erysipela
vaccin
vaccin
foreign
anim
diseas
fad
especi
pose
viral
biohazard
requir
enhanc
secur
biosafeti
measur
eg
foot
mouth
diseas
fmd
bluetongu
diseas
poultri
vaccin
fish
vaccin
new
vaccin
current
undergo
prelicens
develop
evalu
rabi
leptospira
spp
clostridium
spp
vaccin
identifi
highest
prioriti
requir
potenc
test
use
larg
number
anim
involv
signific
pain
distress
exampl
analysi
serial
releas
uk
indic
potenc
test
involv
live
challeng
test
leptospira
spp
rabi
vaccin
account
high
proport
anim
use
batch
potenc
test
vaccin
challeng
test
requir
live
virus
bacteria
hazard
laboratori
worker
livestock
companion
anim
wildlif
also
consid
high
prioriti
eg
rabi
fmd
vaccin
addit
priorit
vaccin
function
protect
antigen
previous
identifi
would
greatli
facilit
success
develop
antigen
quantif
method
final
new
vaccin
includ
high
prioriti
order
encourag
develop
replac
altern
earli
develop
cycl
shown
tabl
sever
vaccin
identifi
high
prioriti
current
use
anim
vaccinationchalleng
toxinneutr
test
altern
serolog
method
either
develop
accept
use
specif
regulatori
author
therefor
valid
refin
method
alreadi
exist
repres
critic
first
step
toward
ultim
goal
identifi
vitro
replac
method
highprior
vaccin
mani
veterinari
vaccin
region
differ
affect
avail
implement
vitro
replac
assay
exampl
usda
publish
vitro
elisa
potenc
test
inactiv
swine
erysipela
vaccin
erysipelothrix
rhusiopathia
european
director
qualiti
medicin
healthcar
edqm
publish
mousebas
serolog
test
european
pharmacopoiea
ph
eur
tabl
edqm
develop
valid
approv
vitro
test
inactiv
newcastl
diseas
vaccin
standard
requir
unit
state
tabl
clearli
improv
intern
commun
harmon
may
expand
number
veterinari
vaccin
replac
method
avail
andor
accept
use
howev
region
differ
diseas
statu
product
composit
number
manufactur
fund
may
affect
prioriti
establish
specif
region
current
veterinari
vaccin
consist
modifi
live
attenu
viru
bacteria
inactiv
kill
virus
bacteria
toxoid
bacterin
toxoid
peptid
subunit
vaccin
genet
engin
product
gener
type
potenc
test
employ
vaccin
manufactur
includ
follow
titrat
live
organ
vitro
occasion
vivo
vitro
assay
elisa
quantit
method
serolog
method
vivo
vitro
vaccinationchalleng
vivo
method
use
either
host
anim
fish
poultri
laboratori
anim
eg
hamster
mice
typic
us
veterinari
vaccin
manufactur
test
use
vitro
titrat
assay
use
vitro
elisa
use
vitro
method
use
vivo
serolog
test
use
vivo
vaccinationchalleng
method
data
exclud
poultri
fish
vaccin
potenc
test
suggest
vitro
method
appli
potenc
test
conduct
veterinari
vaccin
anim
welfar
concern
increas
scientif
accuraci
financi
benefit
associ
vitro
assay
provid
signific
incent
veterinari
vaccin
manufactur
replac
anim
potenc
test
procedur
especi
vaccin
product
releas
without
potenti
concern
repeat
vivo
test
vitro
potenc
test
procedur
current
use
releas
mani
modifi
live
attenu
genet
modifi
vaccin
tabl
wide
use
potenc
releas
inactiv
vaccin
unit
state
usda
center
veterinari
biolog
cvb
publish
mani
supplement
assay
method
sam
provid
detail
valid
protocol
safe
effect
potenc
test
specif
veterinari
vaccin
facilit
use
altern
vitro
method
cvb
regulatori
author
provid
mani
critic
reagent
refer
standard
necessari
conduct
potenc
assay
vitro
potenc
method
quantif
sever
modifi
live
bacteri
vaccin
current
outlin
publicli
avail
usda
sam
exampl
enumer
method
quantifi
colonyform
unit
cfu
specifi
live
organ
describ
brucella
abortu
erysipelothrix
rhusiopathia
avirul
pasteurella
haemolytica
new
name
mannheimia
haemolytica
vaccin
addit
cvb
publish
vitro
potenc
assay
use
indirect
fluoresc
antibodi
stain
inocul
cell
cultur
quantifi
bacteri
titer
chlamydophila
feli
formerli
felin
chlamydia
psittaci
major
bacteri
vaccin
veterinari
use
inactiv
toxoidor
bacterintoxoidbas
rel
modifi
live
bacteri
vaccin
avail
veterinari
use
live
genet
engin
virus
viru
titrat
perform
cell
cultur
use
endpoint
plaqu
format
cytopatholog
indirectli
viru
neutral
virusspecif
serolog
reagent
exampl
vitro
titrat
assay
util
enumer
plaqueform
unit
pfu
avail
felin
caliciviru
felin
rhinotrach
viru
marek
diseas
vaccin
live
viral
vaccin
viru
quantifi
determin
cytopath
effect
primari
cell
cultur
includ
vaccin
follow
porcin
transmiss
gastroenter
porcin
rotaviru
infecti
canin
hepat
canin
adenoviru
canin
distemp
infecti
bursal
diseas
final
modifi
live
viral
vaccin
felin
panleukopenia
canin
parvoviru
quantifi
viru
titer
use
direct
indirect
fluoresc
antibodi
stain
virusinocul
cell
cultur
although
assay
method
approv
usda
often
difficult
estim
procedur
routin
use
releas
vaccin
product
productspecif
valid
requir
howev
estim
approxim
us
veterinari
vaccin
serial
releas
base
vitro
potenc
test
exampl
modifi
live
veterinari
vaccin
potenc
assay
requir
use
anim
provid
tabl
live
vaccin
mink
distemp
viru
vaccin
use
altern
vitro
system
quantifi
viral
content
count
viral
plaqu
grow
chorioallanto
membran
inocul
chicken
embryo
live
chicken
embryoadapt
chlamydophilia
feli
vaccin
embryon
chicken
egg
use
indic
host
system
determin
vaccin
titer
tabl
addit
procedur
avail
titrat
newcastl
diseas
viru
ndv
infecti
bronchiti
viru
ibv
combin
ndvibv
vaccin
inocul
embryon
chicken
egg
order
calcul
egg
infect
dose
major
modifi
live
vaccin
use
vitro
method
potenc
releas
howev
live
attenu
vaccin
ovin
ecthyma
vaccin
sheep
still
requir
target
anim
vaccinationchalleng
potenc
test
mani
inactiv
veterinari
vaccin
especi
bacteri
vaccin
key
hurdl
success
develop
vitro
antigen
quantif
assay
lack
protect
antigen
ident
inclus
complex
adjuv
vaccin
formul
therefor
mani
inactiv
veterinari
vaccin
still
requir
vivo
method
ie
serolog
vaccinationchalleng
method
determin
rel
potenc
howev
specif
exampl
protect
antigen
inactiv
bacteri
vaccin
identifi
use
develop
specif
elisa
quantif
assay
base
comparison
refer
standard
antigen
includ
refer
standard
avail
cvb
productspecif
standard
develop
manufactur
exampl
includ
erysipelothrix
rhusiopathia
bacterin
protein
escherichia
coli
bacterin
test
pilu
pilu
pilu
pilu
develop
swine
erysipela
potenc
test
also
includ
extens
work
develop
human
endpoint
elisa
serolog
test
potenc
determin
variou
leptospira
interrogan
serovar
vitro
elisa
assay
use
measur
rel
potenc
specif
bacterin
compar
suitabl
qualifi
refer
standard
one
avail
cvb
leptospira
interrogan
serovar
test
way
includ
pomona
canicola
grippotyphosa
icterohaemorrhagia
publish
vitro
assay
also
avail
select
inactiv
viru
vaccin
exampl
potenc
inactiv
respiratori
cattl
vaccin
contain
sever
bovin
respiratori
virus
bovin
diarrhea
bvd
bovin
respiratori
syncyti
viru
brsv
bovin
rhinotrach
brv
bovin
parainfluenza
pi
determin
use
elisa
assay
rel
refer
standard
addit
vitro
method
publish
felin
leukemia
viru
antigen
quantif
inactiv
canin
coronaviru
vaccin
vitro
elisa
antigen
quantif
assay
inactiv
ndv
vaccin
develop
valid
edqm
success
transit
vivo
assay
vitro
elisa
aid
fact
strong
correl
antigen
content
antibodi
respons
antigenspecif
antibodi
correl
protect
european
ndv
vaccin
homolog
group
singl
serotyp
compar
oilbas
adjuv
even
distinct
advantag
replac
test
took
almost
year
incorpor
eu
monograph
inactiv
newcastl
vaccin
although
public
eu
monograph
encourag
vitro
assay
option
one
sever
approv
assay
inactiv
newcastl
vaccin
current
includ
monograph
accordingli
difficult
estim
wide
replac
assay
use
vaccin
manufactur
releas
vaccin
product
tabl
provid
specif
exampl
potenc
test
inactiv
veterinari
vaccin
requir
use
anim
exhaust
list
case
gener
method
avail
often
without
detail
methodolog
ad
complex
refer
clearli
indic
assay
use
releas
product
indic
multipl
method
may
avail
approv
specif
vaccin
specif
regulatori
agenc
proceed
edqm
intern
symposium
altern
anim
test
includ
report
provid
vaccin
manufactur
intervet
intern
develop
altern
veterinari
vaccin
potenc
test
accord
report
altern
vitro
potenc
test
inactiv
veterinari
vaccin
describ
individu
monograph
exampl
inactiv
mammalian
veterinari
vaccin
releas
intervet
boxmeer
facil
separ
potenc
test
conduct
three
util
vaccinationchalleng
test
use
serolog
two
use
vitro
techniqu
eu
monograph
provid
detail
descript
test
vitro
test
use
intervet
describ
inactiv
poultri
vaccin
intervet
conduct
potenc
test
three
use
vaccinationchalleng
method
use
serolog
one
serolog
challeng
option
twelv
potenc
test
current
describ
eu
monograph
one
vitro
altern
also
describ
current
use
intervet
fish
vaccin
intervet
use
potenc
test
vaccinationchalleng
test
five
describ
eu
monograph
yet
vitro
altern
provid
although
repres
one
vaccin
manufactur
potenc
releas
inactiv
veterinari
product
fewer
vitro
method
current
exist
provid
indic
potenc
test
util
need
improv
avail
gener
detail
vitro
method
develop
vitro
potenc
assay
highestprior
vaccin
still
use
anim
requir
understand
knowledg
data
gap
delay
introduct
nonanim
assay
understand
protect
antigen
identifi
primari
technic
issu
howev
mani
veterinari
vaccin
especi
bacteri
vaccin
product
protect
antigen
unknown
complex
combin
antigen
therefor
develop
antigen
quantif
test
technic
difficult
demonstr
dose
respons
antigen
protect
target
speci
may
possibl
futur
effort
could
focu
upon
clone
gene
protect
antigen
obtain
right
gene
alreadi
clone
develop
refer
standard
purif
method
could
develop
protect
antigen
antigen
character
appropri
assay
develop
valid
purifi
antigen
may
made
avail
industri
refer
standard
avail
refer
standard
would
enabl
vaccin
manufactur
develop
standard
inhous
evalu
regulatori
agenc
anim
plant
health
inspect
servic
aphi
cvb
biolog
standardis
programm
bsp
edqm
develop
produc
character
distribut
refer
standard
critic
reagent
refer
provid
manufactur
use
develop
assay
compar
direct
indirect
potenc
independ
test
efficaci
ident
puriti
challeng
caus
adjuv
present
mani
veterinari
vaccin
present
second
key
technic
issu
identifi
workshop
particip
challeng
must
address
develop
vitro
replac
altern
typic
vivo
potenc
test
evalu
protect
immun
respons
complet
vaccin
includ
antigen
materi
eg
adjuv
excipi
howev
mani
typic
use
adjuv
miner
oil
aluminum
salt
may
interfer
vitro
quantif
method
therefor
adjuv
would
need
separ
antigen
compon
vaccin
vitro
potenc
test
adjuv
critic
compon
develop
appropri
protect
respons
inactiv
vaccin
addit
vitro
test
may
requir
ensur
qualiti
regardless
antigen
quantif
method
develop
effect
adjuv
immunogen
protect
antigen
also
need
investig
addit
effect
inactiv
vitro
potenc
method
must
investig
recent
studi
show
method
inactiv
case
formaldehyd
oilbas
adjuv
inactiv
newcastl
vaccin
lower
vitro
elisa
potenc
result
affect
vivo
potenc
result
compar
use
inactiv
bpropiolacton
studi
indic
vitro
potenc
result
commerci
newcastl
vaccin
inactiv
formaldehyd
directli
compar
inactiv
use
bpropiolacton
valid
vitro
potenc
assay
begin
assay
initi
develop
involv
establish
relationship
efficaci
target
speci
protect
antigen
protein
must
identifi
purifi
shown
elicit
protect
vaccin
anim
antibodi
protein
neutral
infect
pathogen
extens
valid
continu
assess
assay
precis
accuraci
rugged
toward
transit
implement
use
time
workshop
particip
recommend
follow
highprior
research
develop
valid
activ
current
vivo
potenc
test
inactiv
veterinari
rabi
vaccin
compris
multidilut
vaccinationchalleng
test
mice
tradit
term
nation
institut
health
nih
test
known
highli
variabl
high
frequenc
invalid
result
recent
implement
reduct
refin
altern
test
includ
use
singledilut
vaccin
reduct
result
signific
reduct
anim
usag
approxim
mice
per
test
incorpor
earlier
human
endpoint
paresi
paralysi
convuls
refin
addit
sever
altern
serolog
method
also
develop
rabi
viru
neutral
antibodi
quantifi
serum
immun
anim
two
serolog
method
includ
rapid
fluoresc
focu
inhibit
test
rffit
fluoresc
antibodi
viru
neutral
test
favn
accord
european
pharmacopoeia
rffit
may
use
correl
establish
mous
vaccinationchalleng
vivo
test
recent
studi
demonstr
good
correl
result
rffit
tradit
vivo
challeng
assay
rffit
also
reproduc
within
laboratori
provid
potenti
altern
mous
vaccinationchalleng
assay
fact
european
pharmacopoeia
recent
publish
revis
draft
monograph
incorpor
rffit
potenc
assay
inactiv
rabi
vaccin
veterinari
use
consid
recent
develop
workshop
particip
recommend
focus
intern
workshop
discuss
barrier
intern
implement
rffit
sever
type
antigen
quantif
test
current
develop
inactiv
rabi
veterinari
vaccin
includ
singl
radial
diffus
test
antibodybind
test
elisa
method
although
elisa
assay
reproduc
inexpens
quantit
current
product
specif
reagent
univers
avail
addit
yet
demonstr
antigen
concentr
vaccin
correl
abil
stimul
protect
immun
respons
furthermor
guidanc
andor
recommend
global
regulatori
agenc
necessari
resolv
new
altern
assay
ie
serolog
antigen
quantif
valid
current
highli
variabl
vivo
assay
broad
recognit
gener
consensu
among
workshop
particip
interact
humanveterinari
regulatori
agenc
vaccin
manufactur
expand
interact
would
significantli
increas
appropri
inform
exchang
keep
parti
current
possibl
approach
use
develop
implement
replac
altern
vaccin
potenc
test
potenc
releas
test
use
human
rabi
vaccin
similar
use
veterinari
product
uslicens
rabi
vaccin
human
use
defin
potenc
geometr
mean
two
valid
nih
potenc
test
human
endpoint
defin
eu
similar
vaccinationchalleng
procedur
human
endpoint
also
describ
human
rabi
vaccin
fda
approv
replac
sever
animalbas
immunogen
assay
elisabas
potenc
assay
vaccin
product
includ
human
rabi
vaccin
issu
fact
although
neutral
antigen
well
defin
clear
correl
demonstr
among
amount
antigen
requir
induc
immun
respons
anim
amount
antigen
measur
use
altern
vitro
assay
immun
respons
human
vaccin
consequ
serolog
assay
may
requir
serv
intermedi
step
toward
success
develop
vitro
antigen
quantif
test
although
develop
singl
potenc
test
ie
serolog
antigen
quantif
human
veterinari
rabi
vaccin
desir
goal
may
necessari
adapt
test
productspecif
strainspecif
vaccin
clear
synergi
human
veterinari
rabi
vaccin
workshop
particip
recommend
prioriti
manufactur
regulatori
agenc
worldwid
collabor
develop
valid
refin
replac
assay
rabi
vaccin
product
briefli
current
vivo
leptospira
potenc
test
consist
vaccinationchalleng
procedur
hamster
follow
day
later
lethal
endpoint
vivo
test
time
consum
five
week
expos
laboratori
personnel
live
viabl
leptospira
zoonot
pathogen
usda
recent
develop
sandwich
elisa
altern
vitro
test
use
rabbit
polyclon
captur
specif
mous
monoclon
detect
antibodi
measur
rel
potenc
specif
bacterin
compar
qualifi
refer
standard
sever
leptospira
interrogan
serovar
includ
pomona
canicola
grippotyphosa
icterohaemorrhagia
studi
still
complet
includ
test
adjuv
vaccin
compon
assay
interfer
vivo
vitro
assay
method
current
publish
usda
sam
european
monograph
eg
canin
leptospir
antigen
quantif
method
ph
eur
monograph
leptospira
hardjo
antigen
quantif
method
ph
eur
monograph
summari
develop
valid
vitro
potenc
assay
productand
manufacturerspecif
manufactur
must
perform
necessari
studi
use
specif
regulatori
memorandum
guidanc
throughout
process
secondari
prioriti
workshop
particip
recommend
continu
develop
implement
elisa
antigen
quantif
method
includ
research
effect
adjuv
vaccin
excipi
harmon
test
among
global
regulatori
author
typic
potenc
test
veterinari
clostridium
spp
vaccin
vivo
rabbitmous
toxinneutr
test
current
use
exampl
clostridium
novyi
clostridium
perfringen
tabl
howev
altern
method
clostridi
toxoid
potenc
test
also
develop
publish
exampl
european
regulatori
author
serolog
potenc
test
clostridium
perfringen
clostridium
septicum
vaccin
accept
european
regulatori
author
although
productspecif
valid
still
requir
vaccin
manufactur
clostridium
chauvoei
altern
approach
use
valid
elisa
method
vitro
replac
test
clostridium
hemolyticum
util
toxinneutr
antibodi
character
protect
antigen
describ
potenti
clostridium
protect
antigen
could
evalu
antigen
quantif
method
quantit
elisa
protect
antigen
identifi
gene
clone
right
protect
gene
obtain
sourc
clone
gene
purpos
develop
refer
standard
base
upon
publish
literatur
avail
regulatori
method
replac
toxinneutr
test
specif
clostridium
spp
vaccin
realist
goal
requir
global
recognit
refer
vaccin
identif
target
antigen
vaccin
addit
rabi
vaccin
workshop
particip
agre
synergi
among
expert
human
veterinari
tetanu
vaccin
could
facilit
expedit
develop
replac
potenc
test
vaccin
product
current
unit
state
eu
potenc
test
human
veterinari
vaccin
consist
vaccin
guinea
pig
serolog
evalu
antitetanu
toxoid
antibodi
indirect
elisa
toxinbind
inhibit
tobi
test
effort
develop
replac
test
either
human
veterinari
tetanu
vaccin
imped
fact
toxoid
vaccin
well
character
potenti
analyt
test
includ
physiochem
immunochem
test
requir
much
greater
data
gener
character
valid
inprocess
final
product
character
propos
blueprint
develop
vitro
replac
potenc
test
clostridium
tetani
includ
valid
current
avail
physiochem
immunochem
test
parallel
test
vaccin
vitro
serolog
method
regulatori
accept
implement
focus
coordin
effort
human
veterinari
tetanu
vaccin
expert
develop
replac
implement
plan
given
high
prioriti
workshop
particip
vaccin
foreign
anim
diseas
identifi
high
prioriti
due
biohazard
impos
upon
laboratori
worker
threat
livestock
wildlif
foot
mouth
diseas
econom
import
viral
livestock
diseas
worldwid
infect
domest
wild
clovenfoot
anim
includ
cattl
swine
sheep
goat
deer
control
fmd
proven
difficult
rapid
replic
viru
persist
viru
infect
vaccin
anim
exist
multipl
serotyp
lack
global
avail
effect
vaccin
suppli
inactiv
vaccin
commonli
use
limit
vaccin
short
shelf
life
short
durat
immun
need
includ
mani
antigen
obtain
broad
immun
biosafeti
concern
product
live
viru
improv
vaccin
current
develop
includ
recombin
protein
peptid
vaccin
dna
vaccin
empti
capsid
vaccin
adenovir
fowlpoxvector
vaccin
also
grow
need
marker
fmd
vaccin
would
differenti
infect
vaccin
anim
diva
develop
vaccin
would
signific
vaccin
interfer
diseas
surveil
use
serolog
test
may
result
countri
loss
fmdfree
statu
substanti
econom
loss
superior
function
character
vaccin
develop
greater
opportun
reduc
refin
replac
anim
use
potenc
test
undoubtedli
aris
date
success
vaccin
strategi
develop
recombin
replicationdefect
human
adenoviru
type
express
fmd
capsid
sequenc
solid
efficaci
demonstr
cattl
swine
howev
uncertain
whether
singl
vaccin
approach
success
overcom
shortcom
current
inactiv
vaccin
combin
differ
vaccin
strategi
like
requir
effect
diseas
control
current
vast
major
fmd
infect
occur
asia
africa
south
america
fmdfree
region
includ
north
america
europ
australia
signific
safeti
concern
associ
product
larg
amount
fmd
viru
unit
state
prohibit
live
viru
vaccin
product
mainland
achiev
global
diseas
control
vaccin
improv
themost
longer
durat
immun
requir
especi
region
world
without
advanc
infrastructur
complet
control
erad
fmd
vaccin
surveil
effect
monitor
program
necess
workshop
particip
recommend
poultri
vaccin
prioriti
futur
research
develop
vitro
assay
larg
number
target
anim
current
use
vaccinationchalleng
vaccinationserolog
test
procedur
vitro
potenc
test
live
virus
typic
perform
primari
cell
cultur
use
endpoint
plaqu
format
cytopatholog
exampl
live
viru
poultri
vaccin
use
vitro
potenc
assess
includ
marek
diseas
infecti
bursal
diseas
exampl
nonanim
potenc
test
poultri
vaccin
includ
procedur
titrat
newcastl
diseas
viru
ndv
vaccin
infecti
bronchiti
viru
ibv
vaccin
combin
ndvibv
vaccin
use
embryon
chicken
egg
determin
eid
describ
earlier
vitro
elisa
antigen
quantif
inactiv
ndv
valid
accept
use
eu
addit
antigen
quantif
assay
develop
infecti
bursal
diseas
viru
ibv
vaccin
howev
inadequ
fund
prevent
valid
although
technolog
avail
suffici
resourc
effort
must
still
adequ
appli
valid
replac
potenc
assay
gain
regulatori
approv
final
new
better
character
poultri
vaccin
develop
use
viralvector
system
purifi
recombin
protein
dna
vaccin
altern
vitro
approach
potenc
test
becom
avail
fish
vaccin
potenc
test
highlight
workshop
larg
number
anim
use
includ
unvaccin
control
vaccinationchalleng
procedur
major
fish
vaccin
potenc
releas
test
consist
host
anim
vaccinationchalleng
method
littl
progress
achiev
reduc
refin
replac
use
anim
fish
process
fish
inactiv
bacteri
vaccin
success
use
aquacultur
recent
industri
develop
effect
viral
vaccin
number
avail
fish
vaccin
increas
significantli
increasingli
adjuv
immunostimul
use
enhanc
vaccin
potenc
fish
therebi
complic
abil
develop
refin
replac
potenc
test
procedur
mani
fish
vaccin
correl
serolog
respons
protect
well
establish
either
imped
develop
serolog
potenc
test
howev
protect
antigen
identifi
inactiv
bacteri
vaccin
protect
vibrio
salmonicida
vibrio
anguillarum
diseas
suggest
serolog
antigen
quantif
method
could
develop
select
vaccin
product
final
research
develop
effort
expect
expand
addit
fish
vaccin
enter
market
anim
health
compani
develop
vaccin
aquacultur
use
prioriti
vaccin
describ
requir
signific
invest
time
resourc
complex
associ
move
vivo
test
method
one
requir
anim
cost
associ
signific
research
develop
valid
vitro
vaccin
potenc
test
method
therefor
earli
frequent
interact
regul
strongli
encourag
throughout
process
maxim
likelihood
final
product
accept
regulatori
author
avoid
unnecessari
delay
workshop
particip
agre
primari
impedi
broader
accept
use
avail
nonanim
replac
method
associ
cost
time
requir
vaccin
manufactur
conduct
productspecif
valid
vitro
potenc
assay
specif
vaccin
addit
lack
intern
harmon
altern
potenc
method
often
mean
veterinari
vaccin
manufactur
must
perform
multipl
potenc
releas
test
vaccin
depend
point
manufactur
use
start
point
workshop
particip
recommend
regulatori
agenc
harmon
gener
principl
valid
altern
potenc
test
unit
state
cvb
issu
gener
guidelin
valid
vitro
potenc
assay
rel
potenc
assay
refer
prepar
base
elisa
antigen
quantif
intern
organ
also
play
import
role
harmon
process
intern
cooper
harmonis
technic
requir
registr
veterinari
medicin
product
vich
trilater
program
collabor
among
regulatori
author
anim
health
industri
european
union
japan
unit
state
vich
aim
harmon
technic
requir
registr
veterinari
medicin
product
establish
implement
specif
guidelin
extens
input
review
nation
regulatori
author
vich
establish
auspic
world
organ
anim
health
oie
particip
associ
member
vich
process
support
dissemin
outcom
worldwid
level
http
wwwvichsecorg
vich
guidelin
develop
review
member
intern
anim
health
commun
increas
accept
regulatori
principl
facilit
faster
uniform
implement
exampl
vich
guidelin
adopt
aphi
includ
vich
gl
examin
live
veterinari
vaccin
target
anim
absenc
revers
virul
vich
adopt
us
gl
target
anim
safeti
veterinari
live
inactiv
vaccin
adopt
us
addit
draft
guidelin
develop
vich
consid
waiver
target
anim
batch
safeti
test
addit
harmon
gener
principl
need
harmon
test
procedur
individu
vaccin
antigen
includ
develop
necessari
reagent
exampl
refer
standard
specif
antibodi
virus
bacteria
antigen
access
cvb
us
entiti
aid
develop
vitro
potenc
test
assay
develop
broad
intern
avail
refer
standard
support
nation
region
regulatori
author
would
greatli
help
convert
animalbas
test
nonanim
assay
addit
univers
refer
standard
could
monitor
maintain
organ
oie
usda
world
health
organ
edqm
avail
refer
standard
key
factor
abil
vaccin
manufactur
switch
vitro
replac
assay
exampl
elisa
refer
must
analyz
conjunct
sampl
direct
comparison
test
vaccin
known
refer
use
determin
rel
potenc
rel
potenc
defin
cvb
potenc
product
determin
comparison
approv
refer
vitro
antigen
potenc
assay
unknown
typic
compar
work
refer
gener
master
refer
master
refer
potenc
must
previous
correl
directli
indirectli
host
anim
immunogen
master
refer
correl
host
immunogen
rel
stabil
must
monitor
time
ensur
refer
remain
stabl
storag
current
unit
state
frozen
master
refer
allow
maximum
date
five
year
store
refriger
maximum
date
two
year
date
period
refer
must
requalifi
host
anim
immunogen
test
avoid
use
addit
anim
requalif
workshop
particip
recommend
requalif
conduct
current
accept
potenc
test
develop
new
requalif
test
respons
vaccin
manufactur
requir
signific
resourc
especi
develop
stage
vaccin
manufactur
afford
dedic
resourc
product
older
less
profit
therefor
priorit
veterinari
vaccin
replac
test
potenti
avail
refer
standard
significantli
acceler
anim
test
replac
process
workshop
particip
recommend
stabil
monitor
product
refer
standard
consid
earli
develop
process
recommend
regulatori
author
work
industri
stakehold
set
expect
stabil
monitor
program
stabil
monitor
refer
typic
requir
multipl
previous
valid
test
conduct
schedul
brown
person
commun
test
method
chang
might
stabil
monitor
method
even
refer
standard
consequ
regulatori
agenc
may
requir
flexibl
work
vaccin
manufactur
bridg
refer
standard
methodolog
industri
move
toward
vitro
replac
assay
regulatori
guidanc
also
requir
develop
applic
new
technolog
develop
veterinari
vaccin
genet
engin
rdna
product
includ
inactivatedsubunit
live
inactiv
genedelet
live
vector
gene
insert
product
clearli
vaccin
manufactur
must
decid
product
priorit
specif
nonanim
replac
potenc
test
typic
consid
output
industri
resourc
decis
base
upon
product
revenu
profit
aid
process
expedit
replac
test
suffici
resourc
essenti
develop
maintain
refer
standard
specif
industri
use
addit
broad
access
gener
procedur
guidelin
well
specif
test
procedur
individu
antigen
would
facilit
intern
harmon
replac
assay
develop
use
key
issu
address
avail
fund
research
develop
altern
method
research
develop
fund
industri
stakehold
also
govern
grant
agenc
industri
associ
anim
welfar
advocaci
group
exampl
us
nation
institut
health
may
offer
fund
opportun
veterinari
vaccin
anim
diseas
associ
human
health
rabi
furthermor
academ
research
test
method
altern
promot
manufactur
encourag
appropri
present
andor
publish
research
find
regard
altern
test
method
workshop
particip
also
encourag
increas
avail
regulatori
guidanc
document
public
domain
indic
section
inclus
adjuv
veterinari
vaccin
complic
develop
altern
method
report
interfer
antigen
quantif
assay
consequ
prioriti
given
develop
replac
potenc
test
vaccin
contain
adjuv
adjuv
requir
prioriti
given
adjuv
method
alreadi
exist
separ
adjuv
antigen
newli
develop
adjuv
improv
immun
respons
may
also
difficult
separ
antigen
instanc
regulatori
agenc
may
consid
allow
manufactur
measur
potenc
bulk
materi
addit
adjuv
allow
antigen
test
bulk
materi
addit
characterizationquantit
test
final
product
clear
need
research
simpler
adjuv
andor
method
extract
may
exert
effect
anim
immun
system
directli
interact
antigen
detail
protocol
avail
replac
altern
review
endors
scientif
group
readili
avail
public
domain
facilit
scientif
exchang
consider
exampl
detail
protocol
support
data
valid
method
appear
referenc
european
pharmacopoeia
monograph
freeli
avail
manufactur
scientif
commun
facilit
implement
altern
method
incent
industri
stakehold
develop
valid
implement
altern
method
need
clearli
convey
implement
regulatori
agenc
workshop
particip
identifi
sever
exampl
incent
may
consid
attract
relev
vaccin
manufactur
includ
expedit
regulatori
review
time
waiv
variat
fee
applic
opportun
util
intermitt
vivoin
vitro
parallel
data
expedit
valid
new
vitro
method
first
intern
workshop
unit
state
focus
reduct
refin
replac
anim
use
safeti
potenc
releas
test
human
veterinari
vaccin
key
accomplish
workshop
bring
togeth
expert
industri
academia
govern
area
safeti
potenc
test
human
anim
vaccin
broad
recognit
among
vaccin
manufactur
regulatori
author
gener
consensu
among
particip
intern
workshop
vastli
improv
inform
exchang
global
region
also
regulatori
author
eg
usda
fda
countri
interact
may
acceler
develop
altern
method
prioriti
firmli
establish
present
subsequ
breakout
group
session
allow
particip
clarifi
current
statu
vitro
replac
test
procedur
establish
key
criteria
identifi
vaccin
priorit
focu
inactiv
vaccin
rabi
leptospira
spp
clostridium
spp
diseas
gener
debat
import
outcom
workshop
recommend
similar
intern
workshop
specif
discuss
develop
valid
implement
altern
reduct
refin
replac
potenc
test
assay
rabi
vaccin
human
veterinari
use
workshop
current
schedul
octob
ame
iowa
workshop
reflect
grow
awar
need
altern
test
poultri
fish
vaccin
vaccin
typic
test
larg
number
target
anim
number
fish
vaccin
grown
significantli
last
year
much
research
greater
focu
need
identifi
protect
antigen
replac
test
final
workshop
particip
recogn
uniqu
veterinari
vaccin
need
focu
moremodern
stronger
revenuegener
vaccin
support
cost
new
test
method
develop
workshop
also
brought
attent
develop
use
morecomplex
adjuv
use
multipl
adjuv
gener
solid
sustain
immun
poorer
immunogen
vaccin
lower
vaccin
antigen
level
use
morecomplex
multipl
adjuv
complic
potenc
replac
effort
therefor
highlight
need
much
extens
research
simpler
adjuv
andor
method
extract
protect
antigen
workshop
particip
encourag
signific
number
estim
veterinari
vaccin
especi
modifi
live
viral
bacteri
vaccin
use
vitro
potenc
test
clearli
better
estim
number
veterinari
vaccin
serial
releas
use
replac
method
would
benefici
would
also
focu
discuss
vaccin
replac
potenc
test
yet
avail
use
access
inform
current
state
art
veterinari
vaccin
potenc
test
challeng
procedur
gener
guidelin
univers
avail
result
unnecessari
hindranc
implement
vaccin
product
releas
grow
role
intern
organ
vich
oie
appar
workshop
particip
agre
harmon
guidelin
refer
standard
broad
use
vaccin
commun
would
like
increas
interact
organ
nation
regulatori
group
addit
workshop
particip
clearli
express
need
addit
fund
regulatori
group
allow
greater
avail
key
reagent
eg
refer
standard
vaccin
manufactur
although
vaccin
compani
must
develop
valid
productspecif
assay
refer
standard
would
provid
basi
develop
valid
workshop
set
stage
seri
specif
workshop
identifi
prioriti
vaccin
base
upon
gener
scientif
literatur
present
workshop
broad
intern
consensu
reduc
refin
replac
use
anim
human
veterinari
vaccin
potenc
test
implement
workshop
recommend
discuss
report
expect
advanc
altern
method
veterinari
vaccin
potenc
test
benefit
anim
welfar
ensur
continu
protect
human
anim
health
veterinari
vaccin
session
summar
current
statu
vitro
potenc
test
veterinari
vaccin
identifi
critic
issu
advanc
implement
vitro
replac
assay
current
use
vivo
challeng
toxinneutr
test
focu
effort
criteria
establish
vaccin
highest
prioriti
develop
replac
test
method
base
upon
criteria
highestprior
vaccin
identifi
rabi
leptospira
spp
clostridium
spp
erysipela
foreign
anim
diseas
eg
fmd
poultri
diseas
fish
diseas
workshop
particip
also
priorit
research
develop
valid
activ
necessari
expedit
veterinari
vaccin
potenc
test
fewer
anim
workshop
particip
recogn
special
consider
veterinari
vaccin
due
complex
antigen
materi
inclus
complex
adjuv
acknowledg
mani
case
reductionrefin
test
may
preced
introduct
vitro
replac
assay
combin
number
veterinari
vaccin
valu
veterinari
industri
suggest
prioriti
identifi
correct
highest
chanc
success
implement
consensu
among
workshop
particip
need
univers
avail
reagent
harmon
approach
success
implement
activ
requir
addit
resourc
nation
intern
level
final
workshop
particip
agre
continu
interact
global
vaccin
commun
ie
manufactur
regulatori
agenc
anim
health
organ
human
veterinari
could
expedit
unifi
goal
replac
anim
veterinari
vaccin
potenc
test
